SPRB
$64.30
Spruce Biosciences, Inc.
Intraday
Recent News
Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the best hot stocks to buy according to analysts. On March 9, Spruce Biosciences appointed Dale Hooks as Chief Commercial Officer to lead the company’s transition toward its next phase of growth. Hooks brings nearly 35 years of biopharmaceutical experience to the role, having overseen 21 new product […]
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the most promising micro-cap stocks according to analysts. On February 18, Spruce Biosciences recently concluded successful Type B meetings with the FDA, clearing a path for the BLA submission of tralesinidase alfa enzyme replacement therapy (TA-ERT). The Agency confirmed that existing clinical and natural history data could support […]
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference
Executives from Spruce Biosciences (NASDAQ:SPRB) outlined regulatory plans, clinical data highlights, and commercial considerations for the company’s lead program in Sanfilippo syndrome type B (MPS IIIB) during a fireside chat at Oppenheimer’s 36th Annual Healthcare and Life Sciences Conference. Pr
Spruce Biosciences initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Spruce Biosciences (SPRB) with an Outperform rating and $283 price target. Further to FDA’s confirmation that existing and what the firm views as “compelling” clinical biomarker data could drive accelerated approval, recent Breakthrough Therapy designation bolsters the firm’s conviction ahead of next year’s anticipated approval for Sanfilippo type B syndrome, the analyst tells investors. The firm, which sees “considerable upside for this underappreciated story,”
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls